CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- 4 Open-market sale Director sold 20,573 shares at an average $5.00 ($102,951)
- 4 Open-market sale Director sold 4,422 shares at $5.00 ($22,110)
- 4 Open-market sale Director sold 600 shares at $5.74 ($3,446)
- 4 Open-market sale SVP Strategic Plan. & Bus. Ops sold 1,500 shares at $5.78 ($8,670)
- 4 Open-market sale SVP Strategic Plan. & Bus. Ops sold 1,625 shares at $5.48 ($8,905)
- 4 Open-market sale Director sold 2,147 shares at $5.74 ($12,324)
- 4 Open-market sale Director sold 258 shares at $5.81 ($1,499)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 3,816 shares at $5.24 ($19,996)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 1,908 shares at $5.24 ($9,998)
- 4 Open-market sale SVP Clinical, Med. & Reg.; CMO sold 15,000 shares at an average $5.71 ($85,685)
- 4 Open-market sale SVP Strategic Plan. & Bus. Ops sold 2,250 shares at $5.78 ($13,005)
- 4 Open-market sale SVP Clinical, Med. & Reg.; CMO sold 5,248 shares at an average $5.34 ($28,031)
- 4 Open-market sale SVP Strategic Plan. & Bus. Ops sold 1,950 shares at an average $5.48 ($10,694)
- 4 Other acquisition President, CEO and CFO acquired 10,808.56 shares (other)
- 4 Grant or award SVP Clinical, Med. & Reg.; CMO acquired 36,000 shares (grant or award)
- 4 Open-market sale Director sold 65,027 shares at an average $6.25 ($406,293)
Page 17 of 28 · 550 filings